Shares of Arcus Biosciences, Inc. RCUS, a clinical-stage biopharmaceutical company, declined 14.4% following the announcement that its late-stage STAR-221 study was discontinued for futility. The ...

CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves ...

Shares of Bristol Myers Squibb declined after the company announced that the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten) failed. The phase III study was evaluating ...

Investing.com -- Aligos Therapeutics Inc (NASDAQ:ALGS) stock rose 3.1% on Wednesday following an update on the company’s Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus ...

Shares of Intellia Therapeutics NTLA were down 22.9% yesterday after it announced an update from the ongoing phase III study, evaluating the investigational in vivo genome-editing candidate, nexiguran ...

The Government Service Insurance System said Tuesday it is studying a Philippine Stock Exchange (PSE) proposal to allow state ...

If you want to get better at stock chart analysis, study volume patterns, particularly volume bulges from week to week. Why? Volume is a proxy for institutional investors. The massive trading power of ...

On Tuesday, PepGen Inc. (NASDAQ:PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the ...

Here I use Interpublic Group as a case study, scrutinizing it under elements of an active portfolio management framework. The business produces modestly attractive economics, but is in an earnings ...

Recent survey data suggests that investor apprehension regarding a potential stock market crash could actually serve as a boost for stocks. What Happened: The survey revealed that more than half of ...